Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

NCT06949982 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer (mCRC)
Colorectal Neoplasms

Interventions

COMBINATION_PRODUCT: experimental group x-MAP
DRUG: Regorafenib (BAY 73-4506)

Sponsor

Sergey Orlov, MD